NuCana PLC
NCNA3.630USD
-0.310-7.87%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
124.64KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NuCana PLC Unternehmen
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
NuCana PLC Informationen
BörsenkürzelNCNA
Name des UnternehmensNuCana PLC
IPO-datumSep 28, 2017
CEO- -
Anzahl der mitarbeiter20
WertpapierartDepository Receipt
GeschäftsjahresendeSep 28
AddresseLochside House
StadtEDINBURGH
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlEH12 9DT
Telefon4401313571111
Websitehttps://www.nucana.com/
BörsenkürzelNCNA
IPO-datumSep 28, 2017
CEO- -
Führungskräfte von NuCana PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Nov 1
Aktualisiert: Sat, Nov 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Glass Jacobson Wealth Advisors
0.79%
Global Retirement Partners, LLC
0.21%
Scientech Research LLC
0.07%
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.04%
Andere
98.85%
Aktionäre
Aktionäre
Anteil
Glass Jacobson Wealth Advisors
0.79%
Global Retirement Partners, LLC
0.21%
Scientech Research LLC
0.07%
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.04%
Andere
98.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
1.10%
Venture Capital
0.09%
Investment Advisor/Hedge Fund
0.03%
Hedge Fund
0.02%
Andere
98.77%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
49
23.48K
1.23%
+20.74K
2025Q2
52
554.99K
0.15%
+48.75K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Glass Jacobson Wealth Advisors
75.00
0%
--
--
Jun 30, 2025
Scientech Research LLC
1.27K
0.07%
+1.27K
--
Jun 30, 2025
Sofinnova Investments, Inc
998.00
0.05%
+998.00
--
Feb 14, 2025
Abingworth Management Limited
667.00
0.04%
--
--
Jun 30, 2025
Baader Bank AG
495.00
0.03%
+445.00
+890.00%
Jun 30, 2025
Cetera Investment Advisers LLC
412.00
0.02%
+412.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
357.00
0.02%
+357.00
--
Jun 30, 2025
LPL Financial LLC
100.00
0.01%
+100.00
--
Jun 30, 2025
Jump Financial, LLC
84.00
0%
+84.00
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
